9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 67

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Part 1: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Cmax,  Part 1: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Tmax,  Part 1: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): AUC(0-t), Part 1: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): AUC(0-∞)

Interventions: Tazemetostat,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: June 2018

Completion Date: April 2019

Last  Posted Date: March 14, 2019

Location: University of California, Los Angeles, Los Angeles, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02860286

Was this article helpful?
Dislike 0